KRT17 and neoplasm: Based on a cut-off of ≥25% of tumor cells with strong cytoplasmic staining, 21 (21/48, 43.8%) patients had CK17 high-expressing tumors, and 27 (27/48, 56.2%) had CK17 low-expressing tumors.